AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: cell therapies

Myosin Therapeutics Invited to Present at BioFuture 2026 in New York City

JUPITER, Fla., Oct. 16, 2026 /PRNewswire/ -- Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives...

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovationBrings more than 25 years...

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026,...

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026,...

Fosun International Wins Five Awards at The Asset Corporate Sustainability Leadership Awards 2026, Upgraded to Platinum

HONG KONG, Oct. 13, 2026 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) today announced that it has...

Fosun International Wins Five Awards at The Asset Corporate Sustainability Leadership Awards 2026, Upgraded to Platinum

HONG KONG, Oct. 13, 2026 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) today announced that it has...

Breakthrough T1D Concludes Inaugural Clinical & Research Congress, Highlighting Global Advances in Type 1 Diabetes Research

CRC 2027 Will Take Place in Washington, D.C., October 15-17, 2027PHILADELPHIA, Oct. 12, 2026 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1...

T-MAXIMUM’s B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to...

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead,...

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead,...

Cell Culture Monitoring Biosensors Market to Reach USD 906.56 Million by 2032 – Credence Research

LONDON, Oct. 6, 2026 /PRNewswire/ -- The "Cell Culture Monitoring Biosensors Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2032" report has been added...

Cell Culture Monitoring Biosensors Market to Reach USD 906.56 Million by 2032 – Credence Research

LONDON, Oct. 6, 2026 /PRNewswire/ -- The "Cell Culture Monitoring Biosensors Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2032" report has been added...

Taiwan Biotech Delegation Showcases Regional Innovation in CDMO, Cell Therapy, and Biologics at BioJapan 2026

YOKOHAMA, Japan, Oct. 6, 2026 /PRNewswire/ -- Highlighting regional life sciences innovation, 17 Taiwanese biotech companies and research institutions are gathering at BioJapan 2026 (Oct....

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell therapies